Table 4.
The interaction between SOD2 Val16Ala and SePP1 Ala234Thr SNPs in determining prostate cancer risk in never-smokers and ever-smokers in the CAPS study.
| Never-Smokers | Ever-Smokers | |||||||
|---|---|---|---|---|---|---|---|---|
| Genotype | Controls (n) | Cases (n) | OR (95% CI)* | P | Controls (n) | Cases (n) | OR (95% CI)* | P |
| SEPP1 Codon 234 Ala/Ala | 142 | 252 | 219 | 396 | ||||
| SOD2 Val/Val | 38 | 51 | Referent | 1 | 67 | 73 | Referent | 1 |
| SOD2 Ala/Val + Ala/Ala | 104 | 201 | 1.44 (0.89 to 2.34) | 0.14 | 152 | 323 | 1.97 (1.33 to 2.91) | 0.0007 |
| SEPP1 Codon 234 Ala/Thr + Thr/Thr | 111 | 189 | 167 | 257 | ||||
| SOD2 Val/Val | 27 | 43 | Referent | 1 | 39 | 73 | Referent | 1 |
| SOD2 Ala/Val + Ala/Ala | 84 | 146 | 1.08 (0.62 to 1.87) | 0.80 | 128 | 184 | 0.75 (0.47 to 1.18) | 0.21 |
| P for interaction | 0.43 | 0.0014 | ||||||
*
odds ratio adjusted for age and geographical location, 95% confidence interval
n = Number of subjects